TSN and non-small cell lung carcinoma: Furthermore, here we show that S100A11 silencing sensitized NSCLC cells to treatment with cisplatin, oxaliplatin and 5-fluorouracil and suggest that S100A11 is a novel downstream effector of TSN that promotes resistance of NSCLC cells to chemotherapy.